Table 3.
Probability of one treatment being better
| Observed 3-year EFS | Observed HR | P (HR <1.00) | P (HR <0.81) | P (HR >1.21) | ||||
|---|---|---|---|---|---|---|---|---|
| VIDE | Difference | VDC/IE | Number of events | HR | ln (HR) | |||
| 0.70 | 0.00 | 0.70 | 180 | 1.00 | 0.00 | 0.50 | 0.07 | 0.10 |
| 0.70 | 0.05 | 0.75 | 165 | 0.81 | −0.21 | 0.92 | 0.50 | 0.00 |
| 0.70 | −0.05 | 0.65 | 195 | 1.21 | 0.19 | 0.09 | 0.00 | 0.50 |
| 0.70 | 0.025 | 0.725 | 173 | 0.90 | −0.10 | 0.75 | 0.23 | 0.03 |
| 0.70 | − 0.025 | 0.675 | 188 | 1.10 | 0.10 | 0.25 | 0.02 | 0.27 |
EFS event-free survival, HR hazard ratio, VDC/IE vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide, VIDE vincristine, ifosfamide, doxorubicin and etoposide